ANNEX I

SUMMARY OF PRODUCT CHARACTERISTICS
1. NAME OF THE MEDICINAL PRODUCT

ZALTRAP 25 mg/ml concentrate for solution for infusion

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

One ml of concentrate for solution for infusion contains 25 mg aflibercept*.

One vial of 4 ml of concentrate contains 100 mg of aflibercept.
One vial of 8 ml of concentrate contains 200 mg of aflibercept.

* Aflibercept is produced in a Chinese hamster ovary (CHO) K-1 mammalian expression system by recombinant DNA technology.

Excipient(s) with known effect:

Each 4 ml vial contains 0.484 mmol of sodium, which is 11.118 mg of sodium, and 8 ml vial contains 0.967 mmol of sodium, which is 22.236 mg of sodium.

For the full list of excipients, see section 6.1.

3. PHARMACEUTICAL FORM

Concentrate for solution for infusion (sterile concentrate).
The concentrate is a clear colourless to pale yellow solution.

4. CLINICAL PARTICULARS

4.1 Therapeutic indications

ZALTRAP in combination with irinotecan/5-fluorouracil/folinic acid (FOLFIRI) chemotherapy is indicated in adults with metastatic colorectal cancer (MCRC) that is resistant to or has progressed after an oxaliplatin-containing regimen.

4.2 Posology and method of administration

ZALTRAP should be administered under the supervision of a physician experienced in the use of antineoplastic medicinal products.

Posology
The recommended dose of ZALTRAP, administered as an intravenous infusion over 1 hour, is 4 mg / kg of body weight, followed by the FOLFIRI regimen. This is considered as one treatment cycle.

The FOLFIRI regimen to be used is irinotecan 180 mg/m² intravenous infusion over 90 minutes and folinic acid (dl racemic) 400 mg/m² intravenous infusion over 2 hours at the same time on day 1 using
a Y-line, followed by 5-fluorouracil (5-FU) 400 mg / m² intravenous bolus, followed by 5-FU 2400 mg / m² continuous intravenous infusion over 46 hours.

The treatment cycle is repeated every 2 weeks.

ZALTRAP treatment should be continued until disease progression or unacceptable toxicity occurs.

**Dose modification**

ZALTRAP should be discontinued for (see section 4.4):

- Severe haemorrhage
- Gastrointestinal (GI) perforation
- Fistula formation
- Hypertension that is not adequately controlled with anti-hypertensive therapy or occurrence of hypertensive crisis or hypertensive encephalopathy
- Cardiac failure and ejection fraction decreased
- Arterial thromboembolic events (ATE)
- Grade 4 venous thromboembolic events (including pulmonary embolism)
- Nephrotic syndrome or thrombotic microangiopathy (TMA)
- Severe hypersensitivity reactions (including bronchospasm, dyspnoea, angioedema, and anaphylaxis) (see sections 4.3 and 4.4)
- Compromised wound healing requiring medical intervention
- Posterior reversible encephalopathy syndrome (PRES) (also known as reversible posterior leukoencephalopathy syndrome (RPLS))

ZALTRAP should be temporarily suspended for at least 4 weeks prior to elective surgery (see section 4.4).

<table>
<thead>
<tr>
<th>ZALTRAP/FOLFIRI Treatment delay or dose modification</th>
</tr>
</thead>
<tbody>
<tr>
<td>Neutropenia or thrombocytopenia (see sections 4.4 and 4.8)</td>
</tr>
<tr>
<td>Febrile neutropenia or neutropenic sepsis</td>
</tr>
<tr>
<td>Mild to moderate hypersensitivity reactions to ZALTRAP (including flushing, rash, urticaria, and pruritus) (see section 4.4)</td>
</tr>
<tr>
<td>Severe hypersensitivity reactions (including bronchospasm, dyspnoea, angioedema, and anaphylaxis) (see sections 4.3 and 4.4)</td>
</tr>
</tbody>
</table>

**ZALTRAP Treatment delay and dose modification**
Hypertension  
(see section 4.4)  
ZALTRAP should be temporarily suspended until hypertension is controlled. In case of recurrent medically significant or severe hypertension, despite optimal treatment, ZALTRAP should be suspended until the hypertension is controlled and the dose reduced to 2 mg / kg for subsequent cycles.

Proteinuria  
(see section 4.4)  
ZALTRAP should be suspended when proteinuria ≥2 grams per 24 hours and resumed when proteinuria < 2 grams per 24 hours. If recurrence, the treatment should be suspended until <2 grams per 24 hours and then the dose reduces to 2 mg/kg.

FOLFIRI Dose modification when used in combination with ZALTRAP

| Severe stomatitis and Palmar-Plantar Erythrodysaesthesia syndrome | 5-FU bolus should be reduced and the infusion dose reduced by 20 %. |
| Severe diarrhoea | Irinotecan dose should be reduced by 15-20 %.  
| | If severe diarrhoea recurs on a subsequent cycle, the 5-FU bolus and infusion dose should also be reduced by 20 %.  
| | If severe diarrhoea persists with both dose reductions, FOLFIRI should be discontinued.  
| | Treatment with anti-diarrhoeal medicinal products and rehydration can be used as needed. |

For additional toxicities related to irinotecan, 5-FU, or folinic acid, refer to the current respective summary of product characteristics.

Special populations

Elderly
In the pivotal MCRC study, 28.2 % of patients were aged ≥ 65 and < 75 and 5.4 % of patients were aged ≥ 75. No dose adjustments of ZALTRAP is required in the elderly people.

Hepatic impairment
There have been no formal studies with ZALTRAP in patients with hepatic impairment (see section 5.2). Clinical data suggest that no change in aflibercept dose is required in patients with mild to moderate hepatic impairment. There are no data regarding the administration of aflibercept in patients with severe hepatic impairment.

Renal impairment
There have been no formal studies with ZALTRAP in patients with renal impairment (see section 5.2). Clinical data suggest that no change in starting dose is required in patients with mild to moderate renal impairment. There are very limited data in patients with severe renal impairment; therefore, these patients should be treated with caution.

Paediatric population
There is no relevant use of ZALTRAP in the paediatric population for the indication of metastatic colorectal cancer.

Method of administration
ZALTRAP is to be administered only as an intravenous infusion over 1 hour. Due to hyperosmolality (1000 mOsmol/kg) of the ZALTRAP concentrate, undiluted ZALTRAP concentrate must not be administered as an intravenous push or bolus. ZALTRAP must not be administered as an intravitreal injection (see sections 4.3 and 4.4).

Each vial of concentrate for solution for infusion is for single use (single-dose) only.

Precautions to be taken before handling or administering the medicinal product
For instructions on dilution of the medicinal product before administration, and on infusion sets for administration, see section 6.6.

4.3 Contraindications

Hypersensitivity to aflibercept or to any of the excipients listed in section 6.1.

Ophthalmic / intravitreal use due to hyperosmotic properties of ZALTRAP (see section 4.4).

For contraindications related to FOLFIRI components (irinotecan, 5-FU, and folinic acid), refer to the current respective summary of product characteristics.

4.4 Special warnings and precautions for use

Haemorrhage
An increased risk of haemorrhage, including severe and sometimes fatal haemorrhagic events has been reported in patients treated with aflibercept (see section 4.8).

Patients should be monitored for signs and symptoms of GI bleeding and other severe bleeding. Aflibercept should not be administered to patients with severe haemorrhage (see section 4.2).

Thrombocytopenia has been reported in patients treated with the ZALTRAP/FOLFIRI regimen. Monitoring of complete blood count (CBC) with platelets is recommended at baseline, prior to initiation of each cycle of aflibercept, and as clinically necessary. Administration of the ZALTRAP/FOLFIRI should be delayed until platelet count is \( \geq 75 \times 10^9 / L \) (see section 4.2).

Gastrointestinal perforation
GI perforation including fatal GI perforation has been reported in patients treated with aflibercept (see section 4.8).

Patients should be monitored for signs and symptoms of GI perforation. Aflibercept treatment should be discontinued in patients who experience GI perforation (see section 4.2).

Fistula formation
Fistula formation involving GI and non-GI sites has occurred in patients treated with aflibercept (see section 4.8).

Aflibercept treatment should be discontinued in patients who develop fistula (see section 4.2).

Hypertension
An increased risk of grade 3-4 hypertension (including hypertension and one case of essential hypertension) has been observed in patients treated with the ZALTRAP/FOLFIRI regimen (see section 4.8).

Pre-existing hypertension must be adequately controlled before starting aflibercept. If hypertension cannot be adequately controlled, treatment with aflibercept should not be initiated. It is recommended to monitor blood pressure every two weeks, including before each administration or as clinically
indicated during treatment with aflibercept. In the event of hypertension on aflibercept treatment, blood pressure should be controlled with appropriate anti-hypertensive therapy and blood pressure should be monitored regularly. In case of recurrent medically significant or severe hypertension, despite optimal treatment, aflibercept should be suspended until the hypertension is controlled and the aflibercept dose should be reduced to 2 mg/kg for subsequent cycles. Aflibercept should be permanently discontinued if hypertension cannot be adequately managed with appropriate anti-hypertensive therapy or aflibercept dose reduction, or if hypertensive crisis or hypertensive encephalopathy occurs (see section 4.2).

Hypertension may exacerbate underlying cardiovascular disease. Caution should be exercised when treating patients with history of clinically significant cardiovascular disease such as coronary artery disease, or congestive heart failure with ZALTRAP. Patients with NYHA class III or IV congestive heart failure should not be treated with ZALTRAP.

**Aneurysms and artery dissections**
The use of VEGF pathway inhibitors in patients with or without hypertension may promote the formation of aneurysms and/or artery dissections. Before initiating ZALTRAP, this risk should be carefully considered in patients with risk factors such as hypertension or history of aneurysm.

**Cardiac failure and ejection fraction decreased**
Cardiac failure and ejection fraction decreased have been reported in patients treated with ZALTRAP. Baseline and periodic evaluations of left ventricular function should be considered while the patient is receiving Zaltrap. Patients should be monitored for signs and symptoms of cardiac failure and ejection fraction decreased. Discontinue ZALTRAP in patients who experience cardiac failure and ejection fraction decreased.

**Thrombotic and embolic events**

**Arterial thromboembolic events (ATE)**
ATE (including transient ischaemic attack, cerebrovascular accident, angina pectoris, intracardiac thrombus, myocardial infarction, arterial embolism, and ischaemic colitis) have been observed in patients treated with aflibercept (see section 4.8).

Aflibercept treatment should be discontinued in patients who experience an ATE (see section 4.2).

**Venous thromboembolic events (VTE)**
VTE including deep vein thrombosis (DVT) and pulmonary embolism (infrequently fatal) have been reported in patients treated with aflibercept (see section 4.8). ZALTRAP should be discontinued in patients with life-threatening (Grade 4) thromboembolic events (including pulmonary embolism) (see section 4.2). Patients with Grade 3 DVT should be treated with anticoagulation as clinically indicated, and aflibercept therapy should be continued. In the event of recurrence, despite appropriate anticoagulation, aflibercept treatment should be discontinued. Patients with thromboembolic events of Grade 3 or lower need to be closely monitored.

**Proteinuria**
Severe proteinuria, nephrotic syndrome, and thrombotic microangiopathy (TMA) have been observed in patients treated with aflibercept (see section 4.8).

Proteinuria should be monitored by urine dipstick analysis and/or urinary protein creatinine ratio (UPCR) for the development or worsening of proteinuria before each aflibercept administration. Patients with a dipstick of ≥ 2+ for protein or a UPCR > 1 or a protein/creatinine ratio (PCR)> 100 mg/mmol should undergo a 24-hour urine collection.

Aflibercept administration should be suspended for ≥ 2 grams of proteinuria/24 hours and restarted when proteinuria is <2 grams/24 hours. If there is recurrence, the administration should be suspended
until <2 grams/24 hours and then the dose reduced to 2 mg/kg. Aflibercept treatment should be discontinued in patients who develop nephrotic syndrome or TMA (see section 4.2).

**Neutropenia and neutropenic complications**
A higher incidence of neutropenic complications (febrile neutropenia and neutropenic infection) has been observed in patients treated with the ZALTRAP/FOLFIRI regimen (see section 4.8).

Monitoring of complete blood count (CBC) with differential count is recommended at baseline and prior to initiation of each cycle of aflibercept. Administration of ZALTRAP/FOLFIRI should be delayed until neutrophil count is ≥1.5 x 10⁹/L (see section 4.2). Therapeutic use of G-CSF at first occurrence of grade ≥3 neutropenia and secondary prophylaxis may be considered in patients who may be at increased risk for neutropenia complications.

**Diarrhoea and dehydration**
A higher incidence of severe diarrhoea has been observed in patients treated with the ZALTRAP/FOLFIRI regimen (see section 4.8).

Dose modification of FOLFIRI regimen (see section 4.2), anti-diarrhoeal medicinal products, and rehydration as needed should be instituted.

**Hypersensitivity reactions**
In the pivotal study of MCRC patients, severe hypersensitivity reactions have been reported in patients treated with the ZALTRAP/FOLFIRI regimen (see section 4.8).

In the event of a severe hypersensitivity reaction (including bronchospasm, dyspnoea, angioedema, and anaphylaxis), aflibercept should be discontinued and appropriate medical measures should be administered (see section 4.2).

In the event of a mild to moderate hypersensitivity reaction to ZALTRAP (including flushing, rash, urticaria, and pruritus), aflibercept should be temporarily suspended until the reaction is resolved. Treatment with corticosteroids and/or antihistamines can be initiated as clinically indicated. Pre-treatment with corticosteroids and/or antihistamines may be considered in subsequent cycles (see section 4.2). Caution should be used when retreating patients with prior hypersensitivity reactions as recurrent hypersensitivity reactions have been observed in some patients despite prophylaxis, including corticosteroids.

**Compromised wound healing**
Aflibercept impaired wound healing in animal models (see section 5.3).

Potential for compromised wound healing (wound dehiscence, anastomotic leakage) has been reported with aflibercept (see section 4.8).

Aflibercept should be suspended for at least 4 weeks prior to elective surgery.

It is recommended that aflibercept not be initiated for at least 4 weeks following major surgery and not until the surgical wound is fully healed. For minor surgery such as central venous access port placement, biopsy, and tooth extraction, aflibercept may be initiated/restarted once the surgical wound is fully healed. Aflibercept should be discontinued in patients with compromised wound healing requiring medical intervention (see section 4.2).

**Osteonecrosis of the jaw (ONJ)**
Cases of ONJ have been reported in cancer patients treated with Zaltrap, several of whom had received prior or concomitant treatment with intravenous bisphosphonates, for which ONJ is an identified risk. Caution should be exercised when Zaltrap and intravenous bisphosphonates are administered concurrently or sequentially.
Invasive dental procedures are also an identified risk factor. A dental examination and appropriate preventive dentistry should be considered prior to starting the treatment with Zaltrap. Invasive dental procedures should, if possible, be avoided in patients treated with Zaltrap and who have previously received or are receiving intravenous bisphosphonates (see section 4.8).

Posterior reversible encephalopathy syndrome (PRES)
PRES was not reported in the pivotal phase III study of MCRC patients. In other studies, PRES was reported in patients treated with aflibercept as monotherapy and in combination with other chemotherapies (see section 4.8).

PRES may present with altered mental status, seizure, nausea, vomiting, headache, or visual disturbances. The diagnosis of PRES is confirmed by brain Magnetic Resonance Imaging (MRI).

Aflibercept should be discontinued in patients that develop PRES (see section 4.2).

Elderly
Elderly patients ≥65 years had an increased risk of diarrhoea, dizziness, asthenia, weight loss and dehydration. Careful monitoring is recommended in order to rapidly detect and treat signs and symptoms of diarrhoea and dehydration and to minimize potential risk (see section 4.8).

Renal impairment
There are very limited data available for patients with severe renal impairment treated with aflibercept. No dose adjustment is required for aflibercept (see sections 4.2, 4.8 and 5.2).

Performance status and co-morbidities
Patients with ECOG performance status ≥2 or having significant co-morbidities may be at greater risk for a poor clinical outcome and should be carefully monitored for early clinical deterioration.

Off-label intravitreal use
ZALTRAP is a hypertonic solution, which is not formulated for compatibility with the intraocular environment. ZALTRAP must not be administered as an intravitreal injection (see section 4.3).

ZALTRAP contains sodium
This medicinal product contains up to 22 mg sodium per vial, equivalent to 1.1% of the WHO recommended maximum daily intake of 2 g sodium for an adult.

Traceability
In order to improve the traceability of biological medicinal products, the name and the batch number of the administered product should be clearly recorded.

4.5 Interaction with other medicinal products and other forms of interaction

Population pharmacokinetics analysis and inter study comparisons did not reveal any pharmacokinetic drug-drug interaction between aflibercept and the FOLFIRI regimen.

4.6 Fertility, pregnancy and lactation

Women of childbearing potential / Contraception in males and females
Women of childbearing potential should be advised to avoid becoming pregnant while on ZALTRAP, and should be informed of the potential hazard to the foetus. Women of childbearing potential and fertile males should use effective contraception during and up to a minimum of 6 months after the last dose of treatment.

Pregnancy
There are no data from the use of aflibercept in pregnant women. Studies in animals have shown reproductive toxicity (see section 5.3). As angiogenesis is critical to foetal development, the inhibition
of angiogenesis following administration of ZALTRAP may result in adverse effects on pregnancy. ZALTRAP should be used only if the potential benefit justifies the potential risk during pregnancy. If the patient becomes pregnant while taking ZALTRAP, she should be informed of the potential hazard to the foetus.

**Breast-feeding**
No studies have been conducted to assess the impact of ZALTRAP on milk production, its presence in breast milk or its effects on the breast-fed child.

It is unknown whether aflibercept is excreted in human milk. A risk to the breast-fed child cannot be excluded. A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from ZALTRAP therapy taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.

**Fertility**
Male and female fertility are likely to be compromised during treatment with aflibercept based on studies in monkeys (see section 5.3).

### 4.7 Effects on ability to drive and use machines

ZALTRAP has no or negligible influence on the ability to drive and use machines. If patients are experiencing symptoms that affect their vision or concentration, or their ability to react, they should be advised not to drive or use machines (see section 4.8).

### 4.8 Undesirable effects

**Summary of the safety profile**
The safety of ZALTRAP in combination with FOLFIRI was evaluated in 1,216 patients previously treated for metastatic colorectal cancer, of which 611 patients were treated with ZALTRAP 4 mg/kg every two weeks (one cycle) and 605 patients were treated with placebo/FOLFIRI in a phase III study. Patients received a median number of 9 cycles of the ZALTRAP/FOLFIRI regimen.

The most common adverse reactions (all grades, ≥ 20 % incidence) reported at least 2 % greater incidence for the ZALTRAP/FOLFIRI regimen as compared to the placebo/FOLFIRI regimen in order of decreasing frequency were leucopenia, diarrhoea, neutropenia, proteinuria, increased aspartate aminotransferase (AST), stomatitis, fatigue, thrombocytopenia, increased alanine aminotransferase (ALT), hypertension, weight loss, decreased appetite, epistaxis, abdominal pain, dysphonia, increased serum creatinine, and headache (see Table 1).

The most common reported grades 3-4 reactions (≥5 % incidence) reported at least 2 % greater incidence for the ZALTRAP/FOLFIRI regimen as compared to the placebo/FOLFIRI regimen in order of decreasing frequency, were neutropenia, diarrhoea, hypertension, leucopenia, stomatitis, fatigue, proteinuria, and asthenia (see Table 1).

The most frequent adverse reactions leading to permanent discontinuation in ≥ 1 % of patients treated with the ZALTRAP/FOLFIRI regimen were vascular disorders (3.8 %) including hypertension (2.3 %), infections (3.4 %), asthenia/fatigue (1.6 %, 2.1 %),diarrhoea (2.3 %), dehydration (1 %), stomatitis (1.1 %), neutropenia (1.1 %), proteinuria (1.5 %), and pulmonary embolism (1.1 %).

**Tabulated summary of adverse reactions**
Adverse reactions and laboratory abnormalities reported in patients treated with the ZALTRAP/FOLFIRI regimen compared to patients treated with the placebo/FOLFIRI regimen are listed in Table 1 according to MedDRA system organ class and frequency categories. Adverse reactions in Table 1 are defined as either any adverse clinical reaction or laboratory abnormality
having \( \geq 2\% \) greater incidence (all grades) in the aflibercept treatment group in comparison to the placebo treatment group in the MCRC study including those that do not meet this threshold but were consistent with the anti-VEGF class and were seen in any study with aflibercept. Intensity of the adverse reactions is graded according to NCI CTC version 3.0 (grade \( \geq 3 = G \geq 3 \)). Within each frequency grouping, adverse reactions are presented in the order of decreasing seriousness. Frequencies are based on all grades and defined as: very common (\( \geq 1/10 \)), common (\( \geq 1/100 \) to \(< 1/10 \)); uncommon (\( \geq 1/1,000 \) to \(< 1/100 \)); rare (\( \geq 1/10,000 \) to \(< 1/1,000 \)); very rare (\(< 1/10,000 \)); not known (cannot be estimated from the available data).

Table 1 - Adverse reactions reported in patients treated with the ZALTRAP/FOLFIRI regimen from the MCRC study

<table>
<thead>
<tr>
<th>System Organ Class</th>
<th>Adverse Reaction</th>
<th>Frequency Category</th>
<th>All grades</th>
<th>Grades ( \geq 3 )</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Infections and infestations</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Very common</td>
<td>Infection (1)</td>
<td></td>
<td></td>
<td>Infection (1)</td>
</tr>
<tr>
<td>Common</td>
<td>Neutropenic infection/sepsis (1)</td>
<td></td>
<td></td>
<td>Neutropenic infection/sepsis (1)</td>
</tr>
<tr>
<td></td>
<td>Urinary tract infection</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Nasopharyngitis</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Uncommon</td>
<td></td>
<td></td>
<td></td>
<td>Urinary tract infection</td>
</tr>
<tr>
<td><strong>Blood and lymphatic system disorders</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Very common</td>
<td>Leucopenia (2)</td>
<td></td>
<td></td>
<td>Leucopenia (2)</td>
</tr>
<tr>
<td></td>
<td>Neutropenia (1),(2)</td>
<td></td>
<td></td>
<td>Neutropenia (2)</td>
</tr>
<tr>
<td></td>
<td>Thrombocytopenia (2)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Common</td>
<td>Febrile neutropenia</td>
<td></td>
<td></td>
<td>Febrile neutropenia</td>
</tr>
<tr>
<td></td>
<td>Thrombocytopenia (2)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Immune system disorders</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Common</td>
<td>Hypersensitivity (1)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Uncommon</td>
<td></td>
<td></td>
<td></td>
<td>Hypersensitivity (1)</td>
</tr>
<tr>
<td><strong>Metabolism and nutrition disorders</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Very common</td>
<td>Decreased appetite</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Weight loss</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Common</td>
<td>Dehydration (1)</td>
<td></td>
<td></td>
<td>Dehydration (1)</td>
</tr>
<tr>
<td></td>
<td>Decreased appetite</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Weight loss</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Cardiac disorders</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Uncommon</td>
<td>Cardiac failure</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rare</td>
<td>Ejection fraction decreased</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Nervous system disorders</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Very common</td>
<td>Headache</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Common</td>
<td></td>
<td></td>
<td></td>
<td>Headache</td>
</tr>
<tr>
<td>Uncommon</td>
<td>PRES (1),(4)</td>
<td></td>
<td></td>
<td>PRES (1),(4)</td>
</tr>
<tr>
<td><strong>Vascular disorders</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Very common</td>
<td>Hypertension (1)</td>
<td></td>
<td></td>
<td>Hypertension</td>
</tr>
<tr>
<td></td>
<td>Haemorrhage (1)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>System Organ Class</td>
<td>Adverse Reaction</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>-------------------</td>
<td>------------------</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Frequency Category</td>
<td>All grades</td>
<td>Grades ≥3</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Common</td>
<td>Arterial thromboembolism (1)</td>
<td>Arterial thromboembolism (1)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Venous thromboembolism (1)</td>
<td>Venous thromboembolism (1)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Not known</td>
<td>Aneurysms and artery dissections</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Respiratory, thoracic and mediastinal disorders</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Very common</td>
<td>Dyspnoea</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Epistaxis</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Dysphonia</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Common</td>
<td>Oropharyngeal pain</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Rhinorrhoea</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Uncommon</td>
<td></td>
<td>Dyspnoea</td>
<td>Epistaxis</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Dysphonia</td>
<td>Dysphonia</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Oropharyngeal pain</td>
<td>Oropharyngeal pain</td>
<td></td>
</tr>
<tr>
<td>Gastrointestinal disorders</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Very common</td>
<td>Diarrhoea (1)</td>
<td>Diarrhoea (1)</td>
<td>Stomatitis</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Stomatitis</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Abdominal pain</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Abdominal pain upper</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Common</td>
<td>Rectal haemorrhage</td>
<td>Abdominal pain</td>
<td>Abdominal pain upper</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Fistula (1)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Aphthous stomatitis</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Haemorrhoids</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Proctalgia</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Toothache</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Uncommon</td>
<td>GI perforation (1)</td>
<td>GI perforation (1)</td>
<td>Rectal haemorrhage</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Fistula (1)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Aphthous stomatitis</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Proctalgia</td>
<td></td>
</tr>
<tr>
<td>Hepatobiliary disorders</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Very common</td>
<td>Increased AST (2)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Increased ALT (2)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Common</td>
<td></td>
<td>Increased AST (2)</td>
<td>Increased ALT (2)</td>
<td></td>
</tr>
<tr>
<td>Skin and subcutaneous tissue disorders</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Very common</td>
<td>Palmar-Plantar Erythrodysaesthesia syndrome</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Common</td>
<td>Skin hyperpigmentation</td>
<td>Palmar-Plantar Erythrodysaesthesia syndrome</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Uncommon</td>
<td>Compromised wound healing (1)</td>
<td>Compromised wound healing (1)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>System Organ Class</td>
<td>Adverse Reaction</td>
<td>Frequency Category</td>
<td>All grades</td>
<td>Grades ≥3</td>
</tr>
<tr>
<td>--------------------------------------------</td>
<td>-----------------------------------</td>
<td>--------------------</td>
<td>----------------------------------------------------------------------------</td>
<td>----------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Musculoskeletal and connective tissue disorders</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Uncommon</td>
<td>Osteonecrosis of the Jaw (ONJ)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Renal and urinary disorders</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Very common</td>
<td>Proteinuria (1),(3)</td>
<td></td>
<td>Increased serum creatinine</td>
<td></td>
</tr>
<tr>
<td>Common</td>
<td></td>
<td></td>
<td></td>
<td>Proteinuria (1),(3)</td>
</tr>
<tr>
<td>Uncommon</td>
<td>Nephrotic syndrome (1)</td>
<td></td>
<td></td>
<td>Nephrotic syndrome (1)</td>
</tr>
<tr>
<td></td>
<td>Thrombotic microangiopathy (1)</td>
<td></td>
<td></td>
<td>Thrombotic microangiopathy (1)</td>
</tr>
<tr>
<td>General disorders and administration site conditions</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Very common</td>
<td>Asthenic conditions</td>
<td></td>
<td></td>
<td>Asthenic conditions</td>
</tr>
</tbody>
</table>

Note: Adverse reactions are reported using MedDRA version MEDDRA13.1 and graded using NCI CTC version 3.0

(1) See “Description of selected adverse reactions” in this section
(2) Based on laboratory values (percentages done on patients with laboratory assessments)
(3) Compilation of clinical and laboratory data
(4) Not reported in MCRC study; however, PRES was reported in patients from other studies treated with aflibercept as monotherapy and in combination with chemotherapies other than FOLFIRI

In the pivotal MCRC study, anaemia, nausea, vomiting, constipation, alopecia, increased alkaline phosphatase, and hyperbilirubinaemia occurred in ≥ 20 % of patients. These were comparable between groups, and the difference between groups did not exceed ≥ 2 % incidence for the ZALTRAP/FOLFIRI regimen.

Description of selected adverse reactions

**Haemorrhage**

Patients treated with ZALTRAP have an increased risk of haemorrhage, including severe and sometimes fatal haemorrhagic events. In the pivotal study of MCRC patients, episodes of bleeding/haemorrhage (all grades) was reported in 37.8 % of patients treated with the ZALTRAP/FOLFIRI regimen compared to 19.0 % of patients treated with the placebo/FOLFIRI regimen. The most common reported form of bleeding was minor (grade 1-2) epistaxis occurring in 27.7 % of patients treated with the ZALTRAP/FOLFIRI regimen. Grade 3-4 haemorrhage including GI haemorrhage, haematuria, and post-procedural haemorrhage was reported in 2.9 % of patients receiving the ZALTRAP/FOLFIRI regimen compared with 1.7 % of patients receiving the placebo/FOLFIRI regimen. In other studies, severe intracranial haemorrhage and pulmonary haemorrhage/haemoptysis including fatal events have occurred in patients receiving ZALTRAP (see section 4.4).

**Gastrointestinal perforation**

GI perforation including fatal GI perforation has been reported in patients treated with ZALTRAP. In the pivotal study of MCRC patients, GI perforation (all grades) was reported in 3 of 611 patients (0.5 %) treated with the ZALTRAP/FOLFIRI regimen and 3 of 605 patients (0.5 %) treated with the placebo/FOLFIRI regimen. Grade 3-4 GI perforation events occurred in all 3 patients (0.5 %) treated with the ZALTRAP/FOLFIRI regimen and in 2 patients (0.3 %) treated with the placebo/FOLFIRI regimen. Across the three Phase III placebo-controlled clinical studies (colorectal, pancreatic, and lung cancer populations), the incidence of GI perforation (all grades) was 0.8 % for patients treated with ZALTRAP and 0.3 % for patients treated with placebo. Grade 3-4 GI perforation events occurred in 0.8 % of patients treated with ZALTRAP and 0.2 % of patients treated with placebo (see section 4.4).
Fistula formation
Fistula formation involving GI and non-GI sites has occurred in patients treated with ZALTRAP. In the pivotal study of MCRC patients, fistulas (anal, enterovesical, enterocutaneous, colovaginal, intestinal sites) were reported in 9 of 611 patients (1.5 %) treated with the ZALTRAP/FOLFIRI regimen and 3 of 605 patients (0.5 %) treated with the placebo/FOLFIRI regimen. Grade 3 GI fistula formation occurred in 2 patients treated with ZALTRAP (0.3 %) and in 1 placebo-treated patient (0.2 %). Across the three Phase III placebo-controlled clinical studies (colorectal, pancreatic, and lung cancer populations), the incidence of fistula (all grades) was 1.1 % for patients treated with ZALTRAP and 0.2 % for patients treated with placebo. Grade 3-4 fistula occurred in 0.2 % of patients treated with ZALTRAP and 0.1 % of patients treated with placebo (see section 4.4).

Hypertension
In the pivotal study of MCRC patients, hypertension (all grades) has been reported in 41.2 % of patients treated with ZALTRAP/FOLFIRI and 10.7 % of patients treated with placebo/FOLFIRI. An increased risk of grade 3-4 hypertension (including hypertension and one case of essential hypertension) has been observed in patients receiving the ZALTRAP/FOLFIRI regimen. Grade 3 hypertension (requiring adjustment in existing anti-hypertensive therapy or treatment with more than one medicinal product) was reported in 1.5 % of patients treated with the placebo/FOLFIRI regimen and 19.1 % of patients treated with the ZALTRAP/FOLFIRI regimen. Grade 4 hypertension (hypertensive crisis) was reported in 1 patient (0.2 %) treated with the ZALTRAP/FOLFIRI regimen. Among those patients treated with the ZALTRAP/FOLFIRI regimen developing grade 3-4 hypertension, 54 % had onset during the first two cycles of treatment (see section 4.4).

Thrombotic and embolic events
Arterial thromboembolic events
In the pivotal study of MCRC patients, ATE (including transient ischaemic attack, cerebrovascular accident, angina pectoris, intracardiac thrombus, myocardial infarction, arterial embolism, and ischaemic colitis) were reported in 2.6 % of patients treated with the ZALTRAP/FOLFIRI regimen and 1.5 % of patients treated with the placebo/FOLFIRI regimen. Grade 3-4 events occurred in 11 patients (1.8 %) treated with the ZALTRAP/FOLFIRI regimen and 3 patients (0.5 %) treated with the placebo/FOLFIRI regimen. Across the three Phase III placebo-controlled clinical studies (colorectal, pancreatic, and lung cancer populations), the incidence of ATE (all grades) was 2.3 % for patients treated with ZALTRAP and 1.7 % for patients treated with placebo. Grade 3-4 ATE occurred in 1.7 % of patients treated with ZALTRAP and 1.0 % of patients treated with placebo (see section 4.4).

Venous thromboembolic events
VTE include deep venous thrombosis and pulmonary embolism. In the pivotal study of MCRC patients, all grades VTE occurred in 9.3 % of patients treated with the ZALTRAP/FOLFIRI regimen and 7.3 % of patients treated with the placebo/FOLFIRI regimen. Grade 3-4 VTE occurred in 7.9 % of patients treated with the ZALTRAP/FOLFIRI regimen and in 6.3 % of patients treated with the placebo/FOLFIRI regimen. Pulmonary embolism occurred in 4.6 % of patients treated with the ZALTRAP/FOLFIRI regimen and 3.5 % of patients treated with the placebo/FOLFIRI regimen. Across the three Phase III placebo-controlled clinical studies (colorectal, pancreatic, and lung cancer populations), the incidence of VTE (all grades) was 7.1 % for patients treated with ZALTRAP and 7.1 % for patients treated with placebo.

Proteinuria
In the pivotal study of MCRC patients, proteinuria (compiled from clinical and laboratory data) was reported in 62.2 % patients treated with the ZALTRAP/FOLFIRI regimen compared to 40.7 % patients treated with the placebo/FOLFIRI regimen. Grade 3-4 proteinuria occurred in 7.9 % of patients treated with the ZALTRAP/FOLFIRI regimen compared to 1.2 % of patients treated with the placebo/FOLFIRI regimen. Nephrotic syndrome occurred in 2 patients (0.5 %) treated with the ZALTRAP/FOLFIRI regimen compared to none of the patients treated with the placebo/FOLFIRI regimen. One patient treated with the ZALTRAP/FOLFIRI regimen presenting with proteinuria and
hypertension was diagnosed with thrombotic microangiopathy (TMA). Across the three Phase III placebo-controlled clinical studies (colorectal, pancreatic, and lung cancer populations), the incidence of nephrotic syndrome was 0.5 % of patients treated with ZALTRAP and 0.1 % of patients treated with placebo (see section 4.4).

**Neutropenia and neutropenic complications**
In the pivotal study of MCRC patients, neutropenia (all grades) has been reported in 67.8 % of patients treated with ZALTRAP/FOLFIRI and 56.3 % of patients treated with placebo/FOLFIRI. Grade 3-4 neutropenia was observed in 36.7 % of patients treated with the ZALTRAP/FOLFIRI regimen compared to 29.5 % patients treated with the placebo/FOLFIRI regimen. The most common grade 3-4 neutropenic complication was the occurrence of febrile neutropenia in 4.3 % of patients treated with the ZALTRAP/FOLFIRI regimen compared to 1.7 % of patients treated with the placebo/FOLFIRI regimen. Grade 3-4 neutropenic infection/sepsis occurred in 1.5 % of patients treated with the ZALTRAP/FOLFIRI regimen and 1.2 % of patients treated with the placebo/FOLFIRI regimen (see section 4.4).

**Infections**
Infections occurred at a higher frequency in patients receiving the ZALTRAP/FOLFIRI regimen (46.2 %, all grades; 12.3 %, grade 3-4) than in patients receiving the placebo/FOLFIRI regimen (32.7 %, all grades; 6.9 %, grade 3-4), including urinary tract infection, nasopharyngitis, upper respiratory tract infection, pneumonia, catheter site infection, and tooth infection.

**Diarrhoea and dehydration**
In the pivotal study of MCRC patients, diarrhoea (all grades) has been observed in 69.2 % of patients treated with ZALTRAP/FOLFIRI and 56.5 % of patients treated with placebo/FOLFIRI. Dehydration (all grades) has been observed in 9.0 % of patients treated with ZALTRAP/FOLFIRI and 3.0 % of patients treated with placebo/FOLFIRI. Grade 3-4 diarrhoea was reported in 19.3 % of patients treated with the ZALTRAP/FOLFIRI regimen compared to 7.8 % of patients treated with the placebo/FOLFIRI regimen. Grade 3-4 dehydration was reported in 4.3 % of patients treated with the ZALTRAP/FOLFIRI regimen compared to 1.3 % of patients treated with the placebo/FOLFIRI regimen (see section 4.4).

**Hypersensitivity reactions**
In the pivotal study of MCRC patients, severe hypersensitivity reactions have been reported in 0.3 % of patients treated with the ZALTRAP/FOLFIRI regimen and 0.5 % of patients treated with the placebo/FOLFIRI regimen (see section 4.4).

**Compromised wound healing**
Treatment with ZALTRAP is associated with potential for compromised wound healing (wound dehiscence, anastomotic leakage). In the pivotal study for MCRC, compromised wound healing was reported in 3 patients (0.5 %) treated with the ZALTRAP/FOLFIRI regimen and 5 patients (0.8 %) treated with the placebo/FOLFIRI regimen. Grade 3 compromised wound healing was reported in 2 patients (0.3 %) treated with the ZALTRAP/FOLFIRI regimen and in none of the patients treated with the placebo/FOLFIRI regimen. Across the three Phase III placebo-controlled clinical studies (colorectal, pancreatic, and lung cancer populations), the incidence of compromised wound healing (all grades) was 0.5 % for patients treated with ZALTRAP and 0.4 % for patients treated with placebo. Grade 3-4 compromised wound healing occurred in 0.2 % of patients treated with ZALTRAP and none of patients treated with placebo (see section 4.4).

**Posterior reversible encephalopathy syndrome (PRES)**
PRES was not reported in the pivotal Phase III study of MCRC patients. In other studies, PRES was reported in patients treated with monotherapy ZALTRAP (0.5 %) and in combination with other chemotherapies (see section 4.4).
Additional adverse reactions and laboratory abnormalities reported with a ≥5% difference (all grades) in patients treated with the ZALTRAP/FOLFIRI regimen versus the placebo/FOLFIRI regimen

The following adverse reactions and laboratory abnormalities were reported with a ≥5% difference (all grades) in patients treated with the ZALTRAP/FOLFIRI regimen versus the placebo/FOLFIRI regimen (in order of decreasing frequency): leucopenia (78.3% versus 72.4% all grades; 15.6% versus 12.2% Grades 3-4), increased AST (57.5% versus 50.2% all grades; 3.1% versus 1.7% Grades 3-4), stomatitis (50.1% versus 32.9% all grades; 12.8% versus 4.6% Grades 3-4), fatigue (47.8% versus 39.0% all grades; 12.6% versus 7.8% Grade 3-4), thrombocytopenia (47.4% versus 33.8% all grades; 3.3% versus 1.7% Grades 3-4), increased ALT (47.3% versus 37.1% all grades; 2.7% versus 2.2% Grades 3-4), decreased appetite (31.9% versus 23.8% all grades; 3.4% versus 1.8% Grade 3-4), weight loss (31.9% versus 14.4% all grades; 2.6% versus 0.8% Grades 3-4), dysphonia (25.4% versus 3.3% all grades; 0.5% versus 0 Grades 3-4), headache (22.3% versus 8.8% all grades; 1.6% versus 0.3% Grades 3-4), asthenia (18.3% versus 13.2% all grades; 5.1% versus 3.0% Grades 3-4), Palmar-Plantar Erythrodysesthesia syndrome (11.0% versus 4.3% all grades; 2.8% versus 0.5% Grades 3-4), and skin hyperpigmentation (8.2% versus 2.8% all grades; 0% versus 0 Grades 3-4).

Paediatric population
The safety in paediatric patients has not been established.

Other special populations
Elderly
Of the 611 patients treated with the ZALTRAP/FOLFIRI regimen in the pivotal study of MCRC patients, 172 (28.2%) were aged ≥65 and <75 and 33 (5.4%) were age ≥75. Elderly (≥65 years of age) may be more likely to experience adverse reactions. The incidence of diarrhoea, dizziness, asthenia, weight decrease, and dehydration was increased by ≥5% in elderly compared to younger patients. Elderly people should be closely monitored for the development of diarrhoea and potential dehydration (see section 4.4).

Renal impairment
In patients receiving ZALTRAP, the adverse reactions in patients with mild renal impairment at baseline in three Phase III placebo-controlled clinical studies (N = 352) were comparable with those of patients without renal impairment (N = 642). A limited number of patients having moderate/severe renal impairment at baseline (N = 49) were treated with ZALTRAP. In these patients, non-renal events were generally comparable between patients with renal impairment and those without renal impairment, except a >10% higher incidence in dehydration (all grades) was noted (see section 4.4).

Immunogenicity
As with all therapeutic proteins, there is a potential for immunogenicity with ZALTRAP.

Overall across all clinical oncology studies, similar incidence of low titre anti-drug antibody (ADA) responses (post baseline) in the ADA assay were observed in both patients treated with placebo and ZALTRAP (3.3% and 3.8%, respectively). High-titre antibody responses to aflibercept were not detected in any patients. Seventeen (17) patients treated with ZALTRAP (1.6%) and two (2) placebo-treated patients (0.2%) were also positive in the neutralising antibody assay. In the pivotal study of MCRC patients, positive responses in the ADA assay were observed at higher levels in patients treated with the placebo/FOLFIRI regimen [18/526 (3.4%)] than with the ZALTRAP/FOLFIRI regimen [8/521 (1.5%)]. Positive results in the neutralising antibody assay in the MCRC pivotal study were also higher in patients treated with the placebo/FOLFIRI regimen [2/526 (0.38%)] than with the ZALTRAP/FOLFIRI regimen [1/521 (0.19%)]. There was no observed impact on the pharmacokinetic profile of aflibercept in patients who were positive in the immunogenicity assays.

Given the similar ADA assay results in patients treated with placebo or ZALTRAP, the actual incidence of immunogenicity with ZALTRAP based on these assays is likely to be overestimated.
Immunogenicity data are highly dependent on the sensitivity and specificity of the assay. Additionally, the observed incidence of antibody positivity in an assay may be influenced by several factors, including sample handling, timing of sample collection, concomitant medicinal products, and underlying disease. For these reasons, comparison of the incidence of antibodies to ZALTRAP with the incidence of antibodies to other products may be misleading.

Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in Appendix V.

4.9 Overdose

There is no information on the safety of aflibercept given at doses exceeding 7 mg/kg every 2 weeks or 9 mg/kg every 3 weeks. The most commonly observed adverse reactions at these doses were similar to those observed at the therapeutic dose.

There is no specific antidote to ZALTRAP overdose. Cases of overdose should be managed by appropriate supportive measures particularly with regard to monitoring and treatment of hypertension and proteinuria. The patient should remain under close medical supervision to monitor any adverse reactions (see section 4.8).

5. PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic properties

Pharmacotherapeutic group: Antineoplastic agents, other antineoplastic agents, ATC code: L01XX44

Mechanism of action
Vascular endothelial growth factor A and B (VEGF-A, VEGF-B), and placental growth factor (PIGF) are members of the VEGF family of angiogenic factors that can act as potent mitogenic, chemotactic, and vascular permeability factors for endothelial cells. VEGF-A acts via two receptor tyrosine kinases, VEGFR-1 and VEGFR-2, present on the surface of endothelial cells. PIGF and VEGF-B bind only to VEGFR-1, which is also present on the surface of leucocytes. Excessive activation of these receptors by VEGF-A can result in pathological neovascularisation and excessive vascular permeability. PIGF is also linked to pathological neovascularisation and recruitment of inflammatory cells into tumours.

Aflibercept, also known as VEGF TRAP in the scientific literature, is a recombinant fusion protein consisting of VEGF-binding portions from the extracellular domains of human VEGF receptors 1 and 2 fused to the Fc portion of the human IgG1. Aflibercept is produced by recombinant DNA technology in a Chinese hamster ovary (CHO) K-1 mammalian expression system. Aflibercept is a dimeric glycoprotein with a protein molecular weight of 97 kilodaltons (kDa) and contains glycosylation, constituting an additional 15% of the total molecular mass, resulting in a total molecular weight of 115 kDa.

Aflibercept acts as a soluble decoy receptor that binds to VEGF-A, with higher affinity than its native receptors, as well as the related ligands PIGF and VEGF-B. By acting as a ligand trap, aflibercept prevents binding of endogenous ligands to their cognate receptors and thereby blocks receptor mediated signaling.
Aflibercept blocks the activation of VEGF receptors and the proliferation of endothelial cells, thereby inhibiting the growth of new vessels that supply tumours with oxygen and nutrients.

Aflibercept binds to human VEGF-A (equilibrium dissociation constant $K_D$ of 0.5 pM for VEGF-A$_{165}$ and 0.36 pM for VEGF-A$_{121}$), to human PlGF ($K_D$ of 39 pM for PlGF-2), and to human VEGF-B ($K_D$ of 1.92 pM) to form a stable, inert complex which has no detectable biological activity.

Pharmacodynamic effects
Administration of aflibercept to mice bearing xenotransplant or allotransplant tumours inhibited the growth of various cancer types.

Clinical efficacy and safety
The efficacy and safety of ZALTRAP were evaluated in a randomised, double-blind, placebo-controlled study in patients with metastatic colorectal cancer who had previously been treated with an oxaliplatin-based treatment with or without prior bevacizumab. A total of 1,226 patients were randomised (1:1) to receive either ZALTRAP (N = 612; 4 mg/kg as a 1 hour intravenous infusion on day 1) or placebo (N = 614), in combination with 5-fluouracil plus irinotecan [FOLFIRI: irinotecan 180 mg/m$^2$ intravenous infusion over 90 minutes and folinic acid (dl racemic) 400 mg/m$^2$ intravenous infusion over 2 hours at the same time on day 1 using a Y-line, followed by 5-FU 400 mg/m$^2$ intravenous bolus, followed by 5-FU 2,400 mg/m$^2$ continuous intravenous infusion over 46-hours]. The treatment cycles on both arms were repeated every 2 weeks. Patients were treated until disease progression or unacceptable toxicity. The primary efficacy endpoint was overall survival. Treatment assignment was stratified by the ECOG performance status (0 versus 1 versus 2) and according to prior therapy with bevacizumab (yes or no).

Demographics were well balanced between the treatment arms (age, race, ECOG performance status, and prior bevacizumab status). Of the 1,226 patients randomised in the study, the median age was 61 years, 58.6 % were male, 97.8 % had a baseline ECOG performance status (PS) of 0 or 1, and 2.2 % had a baseline ECOG performance status (PS) of 2. Among the 1,226 randomised patients, 89.4 % and 90.2 % of patients treated with the placebo/FOLFIRI and ZALTRAP/FOLFIRI regimens, respectively, received prior oxaliplatin-based combination chemotherapy in the metastatic/advanced setting. Approximately 10 % of patients (10.4 % and 9.8 % of patients treated with the placebo/FOLFIRI and ZALTRAP/FOLFIRI regimens, respectively) received prior oxaliplatin-based adjuvant chemotherapy and progressed on or within 6 months of completion of adjuvant chemotherapy. Oxaliplatin-based regimens were administered in combination with bevacizumab in 373 patients (30.4 %).

Overall efficacy results for the ZALTRAP/FOLFIRI regimen versus the placebo/FOLFIRI regimen are summarised in Figure 1 and Table 2.
Figure 1 – Overall survival (months) – Kaplan-Meier curves by treatment group – ITT population

![Kaplan-Meier curves by treatment group – ITT population](image)

<table>
<thead>
<tr>
<th></th>
<th>Number at Risk</th>
<th>Survival Probability (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Placebo</td>
<td>ZALTRAP</td>
</tr>
<tr>
<td>314</td>
<td>79.1</td>
<td>81.9</td>
</tr>
<tr>
<td>465</td>
<td>50.3</td>
<td>56.1</td>
</tr>
<tr>
<td>286</td>
<td>30.9</td>
<td>38.5</td>
</tr>
<tr>
<td>131</td>
<td>18.7</td>
<td>29.0</td>
</tr>
<tr>
<td>51</td>
<td>12.0</td>
<td>22.3</td>
</tr>
<tr>
<td>14</td>
<td></td>
<td>53</td>
</tr>
</tbody>
</table>
Table 2 - Main efficacy endpoints\textsuperscript{a} – ITT population

<table>
<thead>
<tr>
<th></th>
<th>Placebo/FOLFIRI</th>
<th>ZALTRAP/FOLFIRI</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>(N = 614)</td>
<td>(N = 612)</td>
</tr>
<tr>
<td>OS</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Number of death events, n (%)</td>
<td>460 (74.9 %)</td>
<td>403 (65.8 %)</td>
</tr>
<tr>
<td>Median overall survival (95 % CI) (months)</td>
<td>12.06 (11.07 to 13.08)</td>
<td>13.50 (12.52 to 14.95)</td>
</tr>
<tr>
<td>Stratified hazard ratio (95 % CI)</td>
<td>0.817 (0.714 to 0.935)</td>
<td></td>
</tr>
<tr>
<td>Stratified log-rank test p-value</td>
<td>0.0032</td>
<td></td>
</tr>
<tr>
<td>PFS\textsuperscript{b}</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Number of events, n (%)</td>
<td>454 (73.9 %)</td>
<td>393 (64.2 %)</td>
</tr>
<tr>
<td>Median PFS (95 % CI) (months)</td>
<td>4.67 (4.21 to 5.36)</td>
<td>6.90 (6.51 to 7.20)</td>
</tr>
<tr>
<td>Stratified hazard ratio (95 % CI)</td>
<td>0.758 (0.661 to 0.869)</td>
<td></td>
</tr>
<tr>
<td>Stratified log-rank test p-value</td>
<td>0.0007</td>
<td></td>
</tr>
<tr>
<td>Overall Response Rate (CR+PR) (95 % CI) (%)\textsuperscript{c}</td>
<td>11.1 (8.5 to 13.8)</td>
<td>19.8 (16.4 to 23.2)</td>
</tr>
<tr>
<td>Stratified Cochran-Mantel-Haenszel test p-value</td>
<td>0.0001</td>
<td></td>
</tr>
</tbody>
</table>

\textsuperscript{a}Stratified on ECOG performance status (0 versus 1 versus 2) and prior bevacizumab (yes versus no).

\textsuperscript{b}PFS (based on tumour assessment by the IRC): Significance threshold is set to 0.0001

\textsuperscript{c}Overall objective response rate by IRC

OS and PFS by stratification factors were performed. A numerically lower treatment effect on OS with the ZALTRAP/FOLFIRI regimen was reported for patients with prior bevacizumab as compared to patients without prior bevacizumab exposure, with no evidence of heterogeneity in treatment effect (non significant interaction test). Results by prior bevacizumab exposure are summarised in Table 3.

Table 3 - OS and PFS by prior bevacizumab exposure\textsuperscript{a} – ITT population

<table>
<thead>
<tr>
<th></th>
<th>Placebo/FOLFIRI</th>
<th>ZALTRAP/FOLFIRI</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>(N = 614)</td>
<td>(N = 612)</td>
</tr>
<tr>
<td>OS</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Patients with prior bevacizumab (n %)</td>
<td>187 (30.5 %)</td>
<td>186 (30.4 %)</td>
</tr>
<tr>
<td>Median OS (95 % CI) (months)</td>
<td>11.7 (9.96 to 13.77)</td>
<td>12.5 (10.78 to 15.47)</td>
</tr>
<tr>
<td>Hazard ratio (95 % CI)</td>
<td>0.862 (0.676 to 1.100)</td>
<td></td>
</tr>
<tr>
<td>Patients with no prior bevacizumab (n %)</td>
<td>427 (69.5 %)</td>
<td>426 (69.6 %)</td>
</tr>
<tr>
<td>Median OS (95 % CI) (months)</td>
<td>12.4 (11.17 to 13.54)</td>
<td>13.9 (12.72 to 15.64)</td>
</tr>
<tr>
<td>Hazard ratio (95 % CI)</td>
<td>0.788 (0.671 to 0.925)</td>
<td></td>
</tr>
<tr>
<td>PFS</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Patients with prior bevacizumab (n %)</td>
<td>187 (30.5 %)</td>
<td>186 (30.4 %)</td>
</tr>
<tr>
<td>Median PFS (95 % CI) (months)</td>
<td>3.9 (3.02 to 4.30)</td>
<td>6.7 (5.75 to 8.21)</td>
</tr>
<tr>
<td>Hazard ratio (95 % CI)</td>
<td>0.661 (0.512 to 0.852)</td>
<td></td>
</tr>
<tr>
<td>Patients with no prior bevacizumab (n %)</td>
<td>427 (69.5 %)</td>
<td>426 (69.6 %)</td>
</tr>
<tr>
<td>Median PFS (95 % CI) (months)</td>
<td>5.4 (4.53 to 5.68)</td>
<td>6.9 (6.37 to 7.20)</td>
</tr>
<tr>
<td>Hazard ratio (95 % CI)</td>
<td>0.797 (0.679 to 0.936)</td>
<td></td>
</tr>
</tbody>
</table>

\textsuperscript{a}As determined per IVRS

Analysis for OS and PFS by ECOG PS was also performed. The hazard ratio (95 % CI) of overall survival was 0.77 (0.64 to 0.93) for ECOG performance status 0 and 0.87 (0.71 to 1.06) for ECOG performance status 1. The hazard ratio (95 % CI) of progression free survival was 0.76 (0.63 to 0.91) for ECOG performance status 0 and 0.75 (0.61 to 0.92) for ECOG performance status 1.
Post-hoc analyses excluding patients who progressed during or within 6 months of adjuvant therapy for patients with or without prior bevacizumab treatment are summarised in Table 4.

Table 4 - Post-hoc analyses excluding adjuvant patientsa,b

<table>
<thead>
<tr>
<th></th>
<th>Placebo/FOLFIRI (N=550)</th>
<th>ZALTRAP/FOLFIRI (N=552)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patients with prior bevacizumab excluding adjuvant only (n (%))</td>
<td>179 (32.5 %)</td>
<td>177 (32.1 %)</td>
</tr>
<tr>
<td>Median OS (95 % CI) (months)</td>
<td>11.7 (9.66 to 13.27)</td>
<td>13.8 (11.01 to 15.87)</td>
</tr>
<tr>
<td>Hazard ratio (95 % CI)</td>
<td>0.812 (0.634 to 1.042)</td>
<td></td>
</tr>
<tr>
<td>Median PFS (95 % CI) (months)</td>
<td>3.9 (3.02 to 4.30)</td>
<td>6.7 (5.72 to 8.21)</td>
</tr>
<tr>
<td>Hazard ratio (95 % CI)</td>
<td>0.645 (0.498 to 0.835)</td>
<td></td>
</tr>
<tr>
<td>Patients with no prior bevacizumab excluding adjuvant only (n (%))</td>
<td>371 (67.5 %)</td>
<td>375 (67.9 %)</td>
</tr>
<tr>
<td>Median overall survival (95 % CI) (months)</td>
<td>12.4 (11.17 to 13.54)</td>
<td>13.7 (12.71 to 16.03)</td>
</tr>
<tr>
<td>Hazard ratio (95 % CI)</td>
<td>0.766 (0.645 to 0.908)</td>
<td></td>
</tr>
<tr>
<td>Median PFS (95 % CI) (months)</td>
<td>5.3 (4.50 to 5.55)</td>
<td>6.9 (6.24 to 7.20)</td>
</tr>
<tr>
<td>Hazard ratio (95 % CI)</td>
<td>0.777 (0.655 to 0.921)</td>
<td></td>
</tr>
</tbody>
</table>

a As determined per IVRS
b OS in ITT population excluding patients who progressed during or within 6 months of adjuvant therapy demonstrated an HR (95 % CI) of 0.78 (0.68 to 0.90) [median OS (95 % CI) with Placebo/FOLFIRI 11.9 months (10.88 to 13.01) and with ZALTRAP/FOLFIRI 13.8 months (12.68 to 15.44)].

Other subgroup analyses for overall survival and progression free survival according to age (< 65; ≥ 65), gender, presence of liver metastasis only, history of prior hypertension, and number of organs involved, showed a treatment effect favouring the ZALTRAP/FOLFIRI regimen over the placebo/FOLFIRI regimen.

In sub-group analysis of overall survival, a benefit consistent with the overall population was observed in patients < 65 years old and ≥ 65 years old who received the ZALTRAP/FOLFIRI regimen.

Exploratory biomarker analyses were undertaken in the VELOUR trial including analyses of RAS mutational status in 482 of 1,226 patients (n = 240 aflibercept; 242 placebo). In patients with RAS wild type tumours the HR (95 % CI) for OS was 0.7 (0.5-1.0) with a median OS of 16.0 months for patients treated with aflibercept, and 11.7 months for the patients treated with placebo. Corresponding data in patients with RAS mutant type tumours showed a HR for OS of 0.9 (0.7-1.2) with median 12.6 and 11.2 months for aflibercept and placebo, respectively. These data are exploratory and the statistical interaction test was non-significant (lack of evidence for heterogeneity in treatment effect between the RAS wild-type and RAS mutant subgroups).

Paediatric population
The European Medicines Agency has waived the obligation to conduct studies with ZALTRAP in all subsets of the paediatric population in adenocarcinoma of the colon and rectum (see section 4.2 for information on paediatric use).

5.2 Pharmacokinetic properties
The pharmacokinetic properties described below have to a large extent been derived from a population pharmacokinetic analysis with data from 1,507 patients with various types of advanced malignancies.
In preclinical tumour models, biologically active doses of aflibercept correlated with those necessary to produce circulating concentrations of free aflibercept in excess of VEGF-bound aflibercept. Circulating concentrations of VEGF-bound aflibercept increase with the aflibercept dose until most available VEGF is bound. Further increases in the aflibercept dose resulted in dose-related increases in circulating free aflibercept concentrations but only small further increases in the VEGF-bound aflibercept concentration.

In patients, ZALTRAP is administered at the dose of 4 mg/kg intravenously every two weeks for which there is an excess of circulating free aflibercept compared to VEGF-bound aflibercept.

At the recommended dose regimen of 4 mg/kg every two weeks, concentration of free aflibercept were near steady-state levels by the second cycle of treatment with essentially no accumulation (accumulation ratio of 1.2 at steady-state compared to the first administration).

**Distribution**
The volume of distribution of free aflibercept at steady-state is approximately 8 litres.

**Biotransformation**
No metabolism studies have been conducted with aflibercept since it is a protein. Aflibercept is expected to degrade to small peptides and individual amino acids.

**Elimination**
Free aflibercept is primarily cleared by binding to endogenous VEGF to form a stable, inactive complex. As with other large proteins, both free and bound aflibercept, are expected to be cleared, more slowly, by other biological mechanisms, such as proteolytic catabolism. At doses greater than 2 mg/kg, free aflibercept clearance was approximately 1.0L/day with a terminal half-life of 6 days.

High molecular weight proteins are not cleared by the renal route, therefore renal elimination of aflibercept is expected to be minimal.

**Linearity/non-linearity**
Consistent with target-mediated drug disposition, free aflibercept exhibits a faster (non-linear) clearance at doses below 2 mg/kg, likely due to the high affinity binding of aflibercept to endogenous VEGF. Linear clearance observed in the dose range of 2 to 9 mg/kg is likely due to non saturable biological mechanisms of elimination such as protein catabolism.

**Other special populations**

*Elderly*
There was no effect of age on the pharmacokinetics of free aflibercept.

*Race*
No effect of race was identified in the population analysis.

*Gender*
Gender was the most significant covariate for explaining the interindividual variability of free aflibercept clearance and volume with a 15.5 % higher clearance and a 20.6 % higher volume of distribution in males than in females. These differences do not affect exposure due to weight-based dosing and no dose modifications based on gender are required.

*Weight*
Weight had an effect on free aflibercept clearance and volume of distribution resulting with a 29 % increase in aflibercept exposure in patients weighing ≥ 100 kg.

*Hepatic impairment*
There have been no formal studies with ZALTRAP in patients with hepatic impairment. In a population pharmacokinetic analysis with data from 1,507 patients with various types of advanced malignancies receiving ZALTRAP with or without chemotherapy, 63 patients with mild hepatic impairment (total bilirubin > 1.0 x – 1.5 x ULN and any AST) and 5 patients with moderate hepatic impairment (total bilirubin > 1.5 x – 3 x ULN and any AST) were treated with ZALTRAP. In these mild and moderate hepatic impairment patients, there was no effect on clearance of aflibercept. There are no data available for patients with severe hepatic impairment (total bilirubin > 3 x ULN and any AST).

**Renal impairment**

There have been no formal studies with ZALTRAP in patients with renal impairment. A population pharmacokinetic analysis was conducted with data from 1,507 patients with various types of advanced malignancies receiving ZALTRAP with or without chemotherapy. This population included; 549 patients with mild renal impairment (CL\textsubscript{CR} between 50-80 ml/min), 96 patients with moderate renal impairment (CL\textsubscript{CR} between 30-50 ml/min), and 5 patients with severe renal impairment (CL\textsubscript{CR} < 30 ml/min). This population pharmacokinetic analysis revealed no clinically meaningful differences in clearance or systemic exposure (AUC) of free aflibercept in patients with moderate and mild renal impairment at the 4 mg/kg dose of ZALTRAP as compared to the overall population studied. No conclusion can be drawn for patients with severe renal impairment due to very limited data available. In the few patients with severe renal impairment, drug exposure was similar to that observed in patients with normal renal function.

5.3 Preclinical safety data

**Animal toxicology and pharmacology**

Weekly/every two weeks intravenous administration of aflibercept to cynomolgus monkeys for up to 6 months resulted in changes in the bone (effects on growth plate and the axial and appendicular skeleton), nasal cavity, kidney, ovary, and adrenal gland. Most aflibercept-related findings were noted from the lowest dose tested corresponding to plasma exposures close to those in patients at the therapeutic dose. Most aflibercept-induced effects were reversible after a 5-month drug free period with the exception of skeletal and nasal cavity findings. Most findings were considered to be related to the pharmacological activity of aflibercept.

Aflibercept administration resulted in a delay in wound healing in rabbits. In full-thickness excisional and incisional skin wound models, aflibercept administration reduced fibrous response, neovascularisation, epidermal hyperplasia/re-epithelialisation, and tensile strength. Aflibercept increased blood pressure in normotensive rodents.

**Carcinogenesis and mutagenesis**

No studies have been conducted to evaluate carcinogenicity or mutagenicity of aflibercept.

**Impairment of fertility**

No specific studies with aflibercept have been conducted in animals to evaluate the effect on fertility. However, results from a repeat dose toxicity study suggest there is a potential for aflibercept to impair reproductive function and fertility. In sexually mature female cynomolgus monkeys inhibition of ovarian function and follicular development was evidenced. These animals also lost normal menstrual cycling. In sexually mature male cynomolgus monkeys a decrease in sperm motility and an increase in incidence of morphological abnormalities of spermatozoa were observed. There was no margin of exposure to patients in relation to these effects. These effects were fully reversible within 8-18 weeks after the last injection.

**Reproductive and development al toxicology**

Aflibercept has been shown to be embryotoxic and teratogenic when administered intravenously to pregnant rabbits every 3 days during the organogenesis period (gestation days 6 to18) at doses approximately 1 to 15 times the human dose of 4 mg/kg every 2 weeks. Observed effects included...
decreases in maternal body weights, an increased number of foetal resorptions, and an increased incidence of external, visceral, and skeletal foetal malformations.

6. PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Sucrose  
Sodium chloride  
Sodium citrate dihydrate  
Citric acid monohydrate  
Polysorbate 20  
Sodium phosphate dibasic heptahydrate  
Sodium phosphate monobasic monohydrate  
Sodium hydroxide and/or hydrochloric acid (for pH adjustment)  
Water for injections

6.2 Incompatibilities

In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products or solvents except those mentioned in section 6.6.

6.3 Shelf life

Unopened vial
3 years

After dilution in the infusion bag
Chemical and physical in-use stability has been demonstrated for 24 hours at 2°C to 8°C and for 8 hours at 25°C.

From a microbiological point of view, the solution for infusion should be used immediately. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 24 hours at 2°C to 8°C unless dilution has taken place in controlled and validated aseptic conditions.

6.4 Special precautions for storage

Store in a refrigerator (2°C – 8°C).  
Store in the original package in order to protect from light.

For storage conditions after dilution of the medicinal product, see section 6.3.

6.5 Nature and contents of container

- 4 ml of concentrate in a 5 ml clear borosilicate glass vial (type I) sealed by a flanged stopper with flip-off cap and inserted coated sealing disc. Pack size of 1 vial or 3 vials.
- 8 ml of concentrate in a 10 ml clear borosilicate glass vial (type I) sealed by a flanged stopper with flip-off cap and inserted coated sealing disc. Pack size of 1 vial.

Not all pack sizes may be marketed.

6.6 Special precautions for disposal and other handling
ZALTRAP is a sterile, preservative-free and non-pyrogenic concentrate, therefore the solution for infusion should be prepared by a healthcare professional using safe-handling procedures and aseptic technique.

Caution should be exercised when handling ZALTRAP, taking into account the use of containment devices, personal protective equipment (e.g. gloves), and preparation procedures.

Preparation of the infusion solution
- Inspect the ZALTRAP vial visually prior to use. The concentrate solution must be clear and without particles.
- Based on the required dose for the patient, withdraw the necessary volume of ZALTRAP concentrate from the vial. More than one vial could be needed for the preparation of the infusion solution.
- Dilute it to the required administration volume with sodium chloride 9 mg/ml (0.9%) solution or 5 % glucose solution for infusion. The concentration of the final ZALTRAP solution for intravenous infusion should be kept within the range of 0.6 mg/ml to 8 mg/ml of aflibercept.
- PVC containing DEHP infusion bags or polyolefin infusion bags should be used.
- The diluted solution should be inspected visually for particulate matter and discoloration prior to administration. If any discoloration or particulate matter is observed, the reconstituted solution should be discarded.
- ZALTRAP is a single-use vial. Do not re-enter the vial after the initial puncture. Any unused concentrate should be discarded.

Administration of the infusion solution
Diluted solutions of ZALTRAP should be administered using infusion sets containing a 0.2 micron polyethersulfone filter.

The infusion sets should be made of one of the following materials:
- polyvinyl chloride (PVC) containing bis(2-ethylhexyl) phthalate (DEHP)
- DEHP free PVC containing triocyl-trimellitate (TOTM)
- polypropylene
- polyethylene lined PVC
- polyurethane

Filters made of polyvinylidene fluoride (PVDF) or nylon must not be used.

Disposal
Any unused medicinal product or waste material should be disposed of in accordance with local requirements.

7. MARKETING AUTHORISATION HOLDER

sanofi-aventis groupe
54, rue La Boétie
75008 Paris
France

8. MARKETING AUTHORISATION NUMBER(S)

EU/1/12/814/001
EU/1/12/814/002
9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

Date of first authorisation: 01 February 2013
Date of latest renewal: 21 September 2017

10. DATE OF REVISION OF THE TEXT

Detailed information on this medicinal product is available on the website of the European Medicines Agency http://www.ema.europa.eu
ANNEX II

A. MANUFACTURER OF THE BIOLOGICAL ACTIVE SUBSTANCE AND MANUFACTURER RESPONSIBLE FOR BATCH RELEASE

B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE

C. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION

D. CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT
A. MANUFACTURER OF THE BIOLOGICAL ACTIVE SUBSTANCE AND MANUFACTURER RESPONSIBLE FOR BATCH RELEASE

Name and address of the manufacturer of the biological active substance

Regeneron Pharmaceuticals, Inc.
81 Columbia Turnpike
Rensselaer, NY 12144
USA

Name and address of the manufacturer responsible for batch release

Sanofi-aventis Deutschland GmbH
Industriepark Höchst
D-65926 Frankfurt am Main
Germany

B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE

Medicinal product subject to restricted medical prescription (see Annex I: Summary of Product Characteristics, section 4.2).

C. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION

- Periodic safety update reports (PSURs)
  The requirements for submission of PSURs for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.

D. CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT

- Risk management plan (RMP)
  The marketing authorisation holder (MAH) shall perform the required pharmacovigilance activities and interventions detailed in the agreed RMP presented in Module 1.8.2 of themarketing authorisation and any agreed subsequent updates of the RMP.

An updated RMP should be submitted:
  - At the request of the European Medicines Agency;
  - Whenever the risk management system is modified, especially as the result of new information being received that may lead to a significant change to the benefit/risk profile or as the result of an important (pharmacovigilance or risk minimisation) milestone being reached.

If the dates for submission of a PSUR and the update of a RMP coincide, they can be submitted at the same time.
ANNEX III

LABELLING AND PACKAGE LEAFLET
A. LABELLING
1. **NAME OF THE MEDICINAL PRODUCT**

ZALTRAP 25 mg / ml concentrate for solution for infusion aflibercept

2. **STATEMENT OF ACTIVE SUBSTANCE(S)**

One vial of 4 ml contains 100 mg of aflibercept (25 mg / ml).
One vial of 8 ml contains 200 mg of aflibercept (25 mg / ml).

3. **LIST OF EXCIPIENTS**

Also contains sucrose, sodium chloride, sodium citrate dihydrate, citric acid monohydrate, polysorbate 20, sodium phosphate dibasic heptahydrate, sodium phosphate monobasic monohydrate, sodium hydroxide and/or hydrochloric acid and water for injections.

4. **PHARMACEUTICAL FORM AND CONTENTS**

Concentrate for solution for infusion

100 mg / 4 ml
1 vial
3 vials

200 mg / 8 ml
1 vial

5. **METHOD AND ROUTE(S) OF ADMINISTRATION**

Single-dose vial.

Read the package leaflet before use.

For intravenous use only. Use only after dilution.

6. **SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN**

Keep out of the sight and reach of children.

7. **OTHER SPECIAL WARNING(S), IF NECESSARY**
8. **EXPIRY DATE**

EXP
Shelf life after dilution: see package leaflet.

9. **SPECIAL STORAGE CONDITIONS**

Store in a refrigerator.
Store in the original package in order to protect from light.

10. **SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE**

11. **NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER**

sanofi-aventis groupe
54, rue La Boétie
75008 Paris
France

12. **MARKETING AUTHORISATION NUMBER(S)**

EU/1/12/814/001 1 vial (100 mg/4 ml)
EU/1/12/814/002 3 vials (100 mg/4 ml)
EU/1/12/814/003 1 vial (200 mg/8 ml)

13. **BATCH NUMBER**

Batch

14. **GENERAL CLASSIFICATION FOR SUPPLY**

15. **INSTRUCTIONS ON USE**

16. **INFORMATION IN BRAILLE**

Justification for not including Braille accepted
17. UNIQUE IDENTIFIER – 2D BARCODE

<2D barcode carrying the unique identifier included.>

18. UNIQUE IDENTIFIER - HUMAN READABLE DATA

PC -
SN -
NN -
## MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS

### VIAL LABEL

1. **NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION**

   ZALTRAP 25 mg / ml sterile concentrate  
   aflibercept  
   For intravenous use only.

2. **METHOD OF ADMINISTRATION**

3. **EXPIRY DATE**

   EXP

4. **BATCH NUMBER**

   Lot

5. **CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT**

   - 100 mg / 4 ml  
   - 200 mg / 8 ml

6. **OTHER**
B. PACKAGE LEAFLET
Package leaflet: Information for the user

ZALTRAP 25 mg / ml concentration for solution for infusion
afibercept

Read all of this leaflet carefully before you are given this medicine because it contains important information for you.
• Keep this leaflet. You may need to read it again, or provide it to future healthcare providers.
• If you have any further questions, ask your doctor, pharmacist or nurse.
• If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. See section 4.

What is this leaflet
1. What ZALTRAP is and what it is used for
2. What you need to know before you are given ZALTRAP
3. How ZALTRAP is given
4. Possible side effects
5. How to store ZALTRAP
6. Contents of the pack and other information

1. What ZALTRAP is and what it is used for

What ZALTRAP is and how it works
ZALTRAP contains the active substance aflibercept, a protein that works by blocking the growth of new blood vessels within the tumour. The tumour needs nutrients and oxygen from blood in order to grow. By blocking the growth of blood vessels, ZALTRAP helps to stop or slow down the growth of the tumour.

What ZALTRAP is used for
ZALTRAP is a medicine used to treat advanced cancers of the colon or rectum (parts of the large intestine) in adults. It will be given with other medicines called ‘chemotherapy’, including ‘5-fluorouracil’, ‘folinic acid’, and ‘irinotecan’.

2. What you need to know before you are given ZALTRAP

Do not use ZALTRAP
• if you are allergic to aflibercept or any of the other ingredients of this medicine (listed in section 6).
• in your eye, since it may severely damage it.

Please also read the package leaflets for the other medicines (‘chemotherapy’) that are part of your treatment, to see if they are suitable for you. If you are unsure, ask your doctor, pharmacist or nurse if there are any reasons why you cannot use these medicines.

Warnings and precautions
Talk to your doctor, pharmacist or nurse before you are given ZALTRAP and during your treatment if:
• you have any bleeding problems or if you notice any bleeding after treatment (see section 4) or if you feel extreme tiredness, weakness, dizziness, or have changes in the colour of your stool. If the bleeding is severe, your doctor will stop your treatment with ZALTRAP. This is because ZALTRAP may increase the risk of bleeding.
- You have any problems with your mouth or teeth such as poor dental health, gum disease, or a planned tooth extraction and especially if you have previously been treated with a bisphosphonate (used to treat or prevent bone disorders). A side effect called osteonecrosis (bone damage in the jaw) has been reported in cancer patients treated with ZALTRAP. You may be advised to have a dental check-up before you start treatment with ZALTRAP. While being treated with ZALTRAP, you should maintain good oral hygiene (including regular teeth brushing) and receive routine dental check-ups. If you wear dentures you should make sure these fit properly. If you also have previously received or are receiving intravenous bisphosphonates dental treatment or dental surgery, (e.g. tooth extractions), should be avoided. Inform your doctor about your dental treatment and tell your dentist that you are being treated with ZALTRAP. Contact your doctor and dentist immediately during and after treatment with ZALTRAP if you experience any problems with your mouth or teeth such as loose teeth, pain or swelling, or non-healing of sores or discharge, as these could be signs of osteonecrosis of the jaw.

- You have illnesses where your gut is inflamed, such as an infected section of the bowel wall (also called ‘diverticulitis’), stomach ulcers or colitis. This is because ZALTRAP may increase the risk of developing holes in the gut wall. If this should happen to you, your doctor will stop your treatment with ZALTRAP.

- You have had any abnormal tube-like connections or passageways inside the body between internal organs and skin or other tissues (also called ‘fistula’). If you develop such a connection or passageway during treatment, your doctor will stop your treatment with ZALTRAP.

- You have high blood pressure. Zaltrap may increase blood pressure (see section 4) and your doctor will need to monitor your blood pressure and may adjust your blood pressure medicines or your dose of ZALTRAP. It is therefore also important to tell your doctor, pharmacist or nurse if you have other heart problems since high blood pressure could make these worse.

- You have or have had an aneurysm (enlargement and weakening of a blood vessel wall) or a tear in a blood vessel wall.

- You experience shortness of breath (dyspnea) when you exert yourself or when you lie down, excessive tiredness or leg swelling which may be signs of heart failure.

- You experience signs of a blood clot (see section 4). The signs of a blood clot may vary depending on where it appears (e.g. lungs, leg, heart or brain) but may include symptoms such as chest pain, coughing, being short of breath or having difficulty breathing. Other signs may include swelling in one or both legs, pain or tenderness in one or both legs, discolouration and warmth of the skin on the affected leg or visible veins. It may also present itself as a sudden numb or weak feeling in the face, arms, or legs. Other signs include feeling confused, problems with sight, walking, coordination or balance, problems in saying words or slurring of speech. If you experience any of these symptoms, talk to your doctor immediately since your doctor may want to treat your symptoms and stop your treatment with ZALTRAP.

- You have kidney problems (protein in the urine), since your doctor will monitor your kidney function and may need to adjust your dose of ZALTRAP.

- Your number of white blood cells is too low. Zaltrap may reduce the number of white cells in your blood and your doctor will monitor your white blood cell count and may give you additional medicines to increase it. If your white blood cells are low, your doctor may need to delay your treatment.

- You have severe or long-lasting diarrhoea, feel sick (nausea) or are being sick (vomiting) - these could cause severe loss of body fluids (called ‘dehydration’). Your doctor may need to treat you with other medicines and/or fluids given intravenously.
• you have ever had any allergies - serious allergic reactions can happen during treatment with ZALTRAP (see section 4). Your doctor may need to treat the allergic reaction or stop your treatment with ZALTRAP.

• you have had a tooth removed or any form of surgery in the last 4 weeks, or you are going to have an operation or a dental or medical procedure, or you have a wound after surgery that has not healed. Your doctor will temporarily stop the treatment before and after surgery.

• you experience fits (seizures). If you experience changes in your vision or confusion, your doctor may stop your treatment with ZALTRAP.

• you are 65 years of age or older and experience diarrhoea, dizziness, weakness, weight loss, or severe loss of body fluids (called ‘dehydration’). Your doctor should monitor you carefully.

• your level of everyday activities is limited or worsens on treatment. Your doctor should monitor you carefully.

If any of the above apply to you (or you are not sure), talk to your doctor, pharmacist or nurse before you are given ZALTRAP and during your treatment.

During treatment, your doctor will perform a number of tests to monitor the function of your body and how the medicine is working. Tests may include blood and urine tests, x-ray or other scanning techniques and/or other tests.

ZALTRAP is given by a drip (infusion) into one of your veins (‘intra-venous’) to treat advanced cancers of the colon or rectum. ZALTRAP must not be injected into the eye, since it may severely damage it.

**Children and adolescents**

This medicine is not for children or adolescents under the age of 18 years because the safety and benefit of using ZALTRAP in children and adolescents have not been shown.

**Other medicines and ZALTRAP**

Tell your doctor, pharmacist or nurse if you are taking, have recently taken or might take any other medicines. This may include medicines obtained without a prescription or herbal medicines.

**Pregnancy, breast-feeding and fertility**

You should not use ZALTRAP during pregnancy unless you and your doctor decide that the benefit for you is greater than any possible risk to you or your unborn baby. If you are a woman that could become pregnant you should use effective contraception (see “Contraception” section below for details on male and female contraception). This medicine may harm your unborn baby since it may stop new blood vessels from forming.

Talk to your doctor before being given this medicine if you are breast-feeding. This is because it is not known if the medicine passes into breast milk.

ZALTRAP may affect male and female fertility. Talk to your doctor for advice if you plan to have or father a child.

**Contraception**

Men and women who can father or have children should use effective contraception:

• during treatment with ZALTRAP and

• for at least 6 months after the last dose of treatment.
Driving and using machines
You may have side effects that affect your sight, concentration or ability to react. If this happens, do not drive or use any tools or machines.

ZALTRAP contains sodium
This medicine contains up to 22 mg sodium (main component of cooking/table salt) in each vial. This is equivalent to 1.1% of the recommended maximum daily dietary intake of sodium for an adult.

3. How ZALTRAP is given
ZALTRAP will be given to you by a doctor or a nurse that is experienced in the use of ‘chemotherapy’. It is given by a drip (infusion) into one of your veins (‘intra-venous’). ZALTRAP must not be injected into the eye, since it may severely damage it.

The medicine must be diluted before it is given. Practical information for handling and administration of ZALTRAP for doctors, nurses and pharmacists when using this medicine is provided with this leaflet.

How much and how often you will receive treatment
- The drip (infusion) lasts for about 1 hour.
- You will usually be given an infusion once every 2 weeks.
- The recommended dose is 4 mg for each kilogram of your body weight. Your doctor will decide the correct dose for you.
- Your doctor will decide how often you will be given the medicine and if you need a change in the dose.

ZALTRAP will be given with other chemotherapy medicines including ‘5-fluorouracil’, ‘folinic acid’, and ‘irinotecan’. Your doctor will decide the appropriate doses for these other chemotherapy medicines.

Treatment will continue as long as your doctor thinks the treatment is of benefit to you, and the side effects are acceptable.

If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.

4. Possible side effects
Like all medicines, this medicine can cause side effects, although not everybody gets them.

The side effects listed below were seen when ZALTRAP was given together with chemotherapy.

Serious side effects
Talk to your doctor straight away, if you notice any of the following serious side effects - you may need urgent medical treatment:
- **Bleeding:** Very common (may affect more than 1 in 10 people) - this includes bleeding from the nose, but may also include severe bleeding in your gut and other parts of the body, which may lead to death. Signs may include feeling very tired, weak, and/or dizzy, or having changes in the colour of your stool.
- **Pain in the mouth, teeth and/or jaw, swelling or non-healing sores in the mouth or jaw, discharge, numbness or a feeling of heaviness in the jaw, or loosening of a tooth:** Uncommon (may affect up to 1 in 100 people) - These symptoms could be signs of bone damage in the jaw (osteonecrosis). Tell your doctor and dentist immediately if you experience such symptoms while being treated with ZALTRAP or after stopping treatment.
• **Holes in the gut** (also called ‘gastro-intestinal perforation’): **Uncommon** (may affect up to 1 in 100 people) - this is a hole in the stomach, food pipe, gut or bowel. This can lead to death. Signs may include stomach pain, being sick (vomiting), fever or chills.

• **Connections or passageways inside the body between internal organs and skin or other tissues** (also called ‘fistula’): **Common** (may affect up to 1 in 10 people) - these abnormal tube-like connections or passageways can form for example, between the gut and your skin. Sometimes, depending on where this happens, you may get an unusual discharge at that place. If you are uncertain contact your doctor.

• **High blood pressure** (also called ‘hypertension’): **Very common** (may affect more than 1 in 10 people) - this may develop or get worse. If blood pressure is not controlled, it may cause stroke, heart and kidney problems. Your doctor should check your blood pressure throughout your treatment.

• **Heart failure** (also called cardiac failure): **Uncommon** (may affect up to 1 in 100 people) – Signs may include shortness of breath when you lie down or when you exert yourself, excessive tiredness or leg swelling.

• **Blocking of the arteries by a blood clot** (also called ‘arterial thrombo-embolic events’): **Common** (may affect up to 1 in 10 people) - this may lead to a stroke or heart attack. Signs may include chest pain or heaviness in the chest, sudden numb or weak feeling in the face, arms, or legs. Other signs include feeling confused; problems with sight, walking, coordination or balance; or problems in saying words or slurring of speech.

• **Blocking of the veins by a blood clot** (also called ‘venous thrombo-emboli events’): **Common** (may affect up to 1 in 10 people) - this may include a blood clot in the lungs or legs. Signs may include chest pain, coughing, being short of breath, difficulty breathing or coughing up blood. Other signs include swelling in one or both legs, pain or tenderness in one or both legs while standing or walking, warmth of the skin on the affected leg, red or discoloured skin in the affected leg or visible veins.

• **Protein in the urine** (also called ‘proteinuria’): **Very common** (may affect more than 1 in 10 people) – this is very commonly seen in tests. This may include swelling of the feet or whole body and may be related to kidney disease.

• **Low white blood cell count** (also called ‘neutropenia’): **Very common** (may affect more than 1 in 10 people) - this can cause serious infections. Your doctor will do blood tests regularly to check your white blood cell counts throughout your treatment. They may also prescribe a medicine called ‘G-CSF’ to help prevent complications if your white blood cell count is too low. Signs of infection may include fever, chills, cough, burning on passing water or muscle ache. You should take your temperature often during treatment with this medicine.

• **Diarrhoea and dehydration**: **Very common** (may affect more than 1 in 10 people) for diarrhoea and **Common** (may affect up to 1 in 10 people) for dehydration - severe diarrhoea and being sick (vomiting) can cause you to lose too much body fluid (called ‘dehydration’) and body salts (electrolytes). Signs may include dizziness especially when going from sitting to standing. You may need to go to the hospital for treatment. Your doctor may give you medicines to stop or treat diarrhoea and being sick (vomiting).

• **Allergic reactions**: **Common** (may affect up to 1 in 10 people) - these may happen within a few minutes after your infusion. Signs of allergic reaction may include rash or itching, skin redness, feeling dizzy or faint, being short of breath, tight chest or throat, or swelling of the face. Tell your doctor or nurse straight away if you have any of these signs during or soon after an infusion of ZALTRAP.
• **Wounds which heal slowly or not at all: Uncommon** (may affect up to 1 in 100 people) - this is when a scar has trouble healing or staying closed, or if a healed wound re-opens. Your doctor will stop this medicine for at least 4 weeks before planned surgery and until the wound is fully healed.

• **A side effect which affects your nervous system** (called ‘posterior reversible encephalopathy syndrome’ or PRES): **Uncommon** (may affect up to 1 in 100 people) - signs may include headache, sight changes, feeling confused or fits with or without high blood pressure.

Talk to your doctor straight away, if you notice any of the side effects above.

**Other side effects include:**

**Very common** (may affect more than 1 in 10 people)
- drop in the number of white blood cells (leucopenia)
- drop in the number of certain cells in the blood that help it to clot (thrombocytopenia)
- decreased appetite
- headache
- nose bleeds
- change of the voice, e.g. developing a hoarse voice
- difficulty when breathing
- painful sores in the mouth
- stomach pain
- swelling and numbness of the hands and feet that happens with chemotherapy (called ‘Palmar-Plantar Erythrodysaesthesia syndrome’)
- feeling tired or weak
- weight loss
- kidney problem with an increase in creatinine (a marker of kidney function)
- liver problem with an increase in liver enzymes.

**Common** (may affect up to 1 in 10 people)
- urinary tract infection
- inflammation inside the nose and upper part of the throat
- pain in the mouth or throat
- runny nose
- haemorrhoids, bleeding or pain in the back passage
- inflammation inside the mouth
- toothache
- changes in the colour of the skin.

**Uncommon** (may affect up to 1 in 100 people)
- an increase in protein in the urine, an increase in cholesterol in the blood, and swelling from excess fluid (oedema) (also called ‘nephrotic syndrome’)
- blood clot in very small blood vessels (also called ‘thrombotic microangiopathy’).

**Not known** (frequency cannot be estimated from the available data)
- an enlargement and weakening of a blood vessel wall or a tear in a blood vessel wall (aneurysms and artery dissections)

**Reporting of side effects**
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in **Appendix V**. By reporting side effects you can help provide more information on the safety of this medicine.
5. **How to store ZALTRAP**

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date which is stated on the outer carton and on the label of the vial after EXP. The expiry date refers to the last day of that month.

Store in a refrigerator (2°C - 8°C).
Store in the original package in order to protect from light.

Information about storage and the time to use ZALTRAP, after it has been diluted and is ready to use, is described in the ‘Practical information for healthcare professionals on preparation and handling of ZALTRAP 25 mg / ml concentrate for solution for infusion’ at the end of this leaflet.

Do not use ZALTRAP if you notice particles or discolouration of the medicine in the vial or infusion bag.

Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.

6. **Contents of the pack and other information**

**What ZALTRAP contains**

- The active substance is aflibercept. One ml of concentrate contains 25 mg aflibercept. One 4 ml vial of concentrate contains 100 mg aflibercept. One 8 ml vial of concentrate contains 200 mg aflibercept.
- The other ingredients are: sucrose, sodium chloride, sodium citrate dihydrate, citric acid monohydrate, polysorbate 20, sodium phosphate dibasic heptahydrate, sodium phosphate monobasic monohydrate, sodium hydroxide and/or hydrochloric acid and water for injections.

**What ZALTRAP looks like and contents of the pack**

ZALTRAP is a concentrate for solution for infusion (sterile concentrate). The concentrate is a clear, colourless to pale yellow solution.

- 4 ml of concentrate in a 5 ml clear borosilicate glass vial (type I), sealed by a flanged stopper with flip-off cap and inserted coated sealing disc. Pack size of 1 vial or 3 vials.
- 8 ml of concentrate in a 10 ml clear borosilicate glass vial (type I), sealed by a flanged stopper with flip-off cap and inserted coated sealing disc. Pack size of 1 vial.

Not all pack sizes may be marketed.

**Marketing Authorisation Holder**

sanofi-aventis groupe
54, rue La Boétie
75008 Paris
France

**Manufacturer**

Sanofi-Aventis Deutschland GmbH
Industriepark Hoechst
65926 Frankfurt am Main
Germany

For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:
België/Belgique/Belgien
Sanofi Belgium
Tél/Tel: +32 (0)2 710 54 00

България
sanofi-aventis Bulgaria EOOD
Tel.: +359 (0)2 970 53 00

Česká republika
sanofi-aventis, s.r.o.
Tel: +420 233 086 111

Danmark
Sanofi A/S
Tlf: +45 45 16 70 00

Deutschland
Sanofi-Aventis Deutschland GmbH
Tel.: 0800 04 36 996
Tel. aus dem Ausland: +49 69 305 70 13

Eesti
sanofi-aventis Estonia OÜ
Tel: +372 627 34 88

Ελλάδα
sanofi-aventis AEBE
Τηλ.: +30 210 900 16 00

España
sanofi-aventis, S.A.
Tel: +34 93 485 94 00

France
sanofi-aventis France
Tél: 0 800 222 555
Appel depuis l’étranger : +33 1 57 63 23 23

Hrvatska
sanofi-aventis Croatia d.o.o.
Tel: +385 1 600 34 00

Ireland
sanofi-aventis Ireland Ltd. T/A SANOFI
Tel: +353 (0) 1 403 56 00

Ísland
Vistor hf.
Sími: +354 535 7000

Italia
Sanofi S.r.l.
Tel: 800536389

Lietuva
UB “SANOFI-AVENTIS LIETUVA”
Tel: +370 5 2755224

Luxembourg/Luxemburg
Sanofi Belgium
Tél/Tel: +32 (0)2 710 54 00 (Belgique/Belgien)

Magyarország
SANOFI-AVENTIS zrt.
Tel.: +36 1 505 0050

Malta
Sanoﬁ S.r.l.
Tel: +39 02 39394275

Nederland
Genzyme Europe B.V.
Tel: +31 (0)20 245 4000

Norge
sanofi-aventis Norge AS
Tlf: +47 67 10 71 00

Österreich
sanofi-aventis GmbH
Tel: +43 1 80 185 – 0

Polska
sanofi-aventis Sp. z o.o.
Tel.: +48 22 280 00 00

Portugal
Sanofi - Produtos Farmacêuticos, Lda.
Tel: +351 21 35 89 400

România
Sanofi Romania SRL
Tel: +40 (0) 21 317 31 36

Slovenija
sanofi-aventis d.o.o.
Tel: +386 1 560 48 00

Slovenská republika
sanofi-aventis Slovakia s.r.o.
Tel: +421 2 33 100 100

Suomi/Finland
Sanofi Oy
Puh/Tel: +358 (0) 201 200 300
This leaflet was last revised in

**Other sources of information**

Detailed information on this medicine is available on the European Medicines Agency web site:

The following information is intended for healthcare professionals only:

PRACTICAL INFORMATION FOR HEALTHCARE PROFESSIONALS ON PREPARATION AND HANDLING OF ZALTRAP 25 mg/ml CONCENTRATE FOR SOLUTION FOR INFUSION

This information supplements the sections 3 and 5 for the user. It is important that you read the entire content of this procedure prior to the preparation of infusion solution.

ZALTRAP is a sterile, preservative-free and non-pyrogenic concentrate, therefore the solution for infusion should be prepared by a healthcare professional using safe-handling procedures and aseptic technique. Caution should be exercised when handling ZALTRAP, taking into account the use of containment devices, personal protective equipment (e.g. gloves), and preparation procedures.

Preparation of the infusion solution

• Inspect the ZALTRAP vial visually prior to use. The concentrate solution must be clear and without particles.
• Based on the required dose for the patient, withdraw the necessary volume of ZALTRAP concentrate from the vial. More than one vial could be needed for the preparation of the infusion solution.
• Dilute it to the required administration volume with sodium chloride 9 mg/ml (0.9 %) solution or 5 % glucose solution for infusion. The concentration of the final ZALTRAP solution for intravenous infusion should be kept within the range of 0.6 mg/ml to 8 mg/ml of aflibercept.
• PVC containing DEHP infusion bags or polyolefin infusion bags should be used.
• The diluted solution should be inspected visually for particulate matter and discolouration prior to administration. If any discoloration or particulate matter is observed, the reconstituted solution should be discarded.
• ZALTRAP is a single-use vial. Do not re-enter the vial after the initial puncture. Any unused concentrate should be discarded.

Shelf-life after dilution in the infusion bag

Chemical and physical in-use stability has been demonstrated for 24 hours at 2°C to 8°C and for 8 hours at 25°C.

From a microbiological point of view, the solution for infusion should be used immediately. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 24 hours at 2°C to 8°C unless dilution has taken place in controlled and validated aseptic conditions.

Method of administration

ZALTRAP is to be administered only as an intravenous infusion over 1 hour. Due to hyperosmolality (1000 mOsmol/kg) of the ZALTRAP concentrate, undiluted ZALTRAP concentrate must not be administered as an intravenous push or bolus. ZALTRAP must not be administered as an intravitreal injection (see section 2 of the package leaflet).

Each vial of concentrate for solution for infusion is for single use (single-dose) only.

Diluted solutions of ZALTRAP should be administered using infusion sets containing a 0.2 micron polyethersulfone filter.
The infusion sets should be made of one of the following materials:
• polyvinyl chloride (PVC) containing bis(2-ethylhexyl) phthalate (DEHP)
• DEHP free PVC containing trioctyl-trimellitate (TOTM)
• polypropylene
• polyethylene lined PVC
• polyurethane

Filters made of polyvinylidene fluoride (PVDF) or nylon must not be used.

Disposal
Any unused medicine or waste material should be disposed of in accordance with local requirements.